Li Yan-Jiang, Zheng Bao-zhong, Zhou Zun-lin
Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Jan;35(1):57-9.
To probe into the expression and clinical significance of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in urinary transitional cell carcinoma.
Expression of uPA and uPAR were detected in 50 cases of renal pelvis and ureter carcinoma and 40 cases of bladder cancer immunohistochemically.
The positive rates of uPA and uPAR were closely correlated to the grade and the stage of urinary transitional cell carcinoma (r = 0.979, P < 0.01), whereas uPA and uPAR were not detected in normal kidney, ureter and bladder tissue.
uPA and uPAR are highly expressed in urinary transitional cell carcinoma and they may be responsible for the tumor invasion and metastasis.
探讨尿激酶型纤溶酶原激活剂（uPA）及其受体（uPAR）在尿路上皮细胞癌中的表达及临床意义。
采用免疫组化法检测50例肾盂及输尿管癌和40例膀胱癌中uPA和uPAR的表达。
uPA和uPAR的阳性率与尿路上皮细胞癌的分级和分期密切相关（r = 0.979，P < 0.01），而在正常肾、输尿管和膀胱组织中未检测到uPA和uPAR。
uPA和uPAR在尿路上皮细胞癌中高表达，它们可能与肿瘤的侵袭和转移有关。
Zotero 插件